Live
Dr Reddy’s Laboratories has reported a consolidated net profit of Rs 570.8 crore in the first quarter of FY22, a 1.5 per cent dip on a year-on-year basis. In comparison, revenue from operations grew by 11.4 per cent to Rs 4,919.4 crore during the quarter.
Dr Reddy’s said it had received a subpoena (written order to attend court to give evidence) from the American market regulator Securities and Exchange Commission (SEC) for producing documents concerning the Commonwealth of Independent States (CIS) geographies.
The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22 and the US market regulator’s subpoena on documents for CIS geographies.
- Piramal Finance Q2 Profit Jumps 67% to Rs 545 Cr
- IRDAI plans lower commissions, minor hit for PSU Banks
- SML Mahindra Q2 Sales Rise 20.7% but Profit Falls 44%
- Hindustan Zinc Q2 Profit Jumps 142% to Record Rs 6,412 Cr
- Aeroflex Industries Gets Indian Patent for 3D Hose Design Tool
Kunal Randeria of Edelweiss Securities said the disappointing numbers, the big margin miss, and the subpoena by the US SEC following an investigation into practices in Ukraine were the reasons behind the stock fall.
Stock Covered in the news
